Senate Bill 483 Passes House and Senate

 

Tonight the U.S. House of Representatives passed its version of Senate Bill 483, Ensuring Patient Access & Drug Enforcement Act of 2016.  The Senate passed the bill on March 17, 2016.    Sponsor Orrin Hatch (R-Utah) introduced the bill  on February 12, 2014, and continued to championed it through the Senate Judiciary Committee.  A big THANK YOU for the many letters and personal contacts that were made to U.S. Senators and Representatives in response to the call to action by the National Fibromyalgia & Chronic Pain Association in February 2016.

The bill is of particular interest to patients with chronic pain and DEA registrants authorized to distribute or prescribe controlled substances (particularly Schedule II) because it:

#1  Requires an order to show cause as to why such a registration should not be denied, revoked, or suspended to:

  • (1) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated;
  • (2) direct the applicant or registrant to appear before the Attorney General at a specific place and time within 30 days after receipt of the order; and
  • (3) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before such appearance. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modifications to such plan.
  • Makes such requirements inapplicable to the issuance of an immediate suspension order.

#2  Directs the Department of Health and Human Services, acting through the Food and Drug Administration and the Centers for Disease Control and Prevention, to submit a report identifying:

  • (1) obstacles to legitimate patient access to controlled substances;
  • (2) issues with diversion of controlled substances; and
  • (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

The National Fibromyalgia & Chronic Pain Association is very appreciative to Senator Hatch and his Legislative Assistants, Members of the Senate Judiciary Committee, and the House of Representatives for supporting this important legislation.  We strongly urge President Obama to sign the bills into law immediately.

Hydrocodone Rescheduling: The First 100 Days Report

hyrdo

Hydrocodone Rescheduling: The First 100 Days

Authors: Jan Chambers, Rae Marie Gleason, Kenneth L. Kirsh, PhD, Robert Twillman, PhD, Lynn Webster, MD, Jon Berner, MD, PhD,  Jeff Fudin, PharmD, FCCP, FASHP, Steven D. Passik, PhD

The paper’s objective was to conduct an Internet patient survey through the NFMCPA on reactions to the first 100 days following the rescheduling of hydrocodone to a Controlled Substance Schedule II medication.  With expert consensus, the investigative team repurposed some questions from prior NFMCP Internet surveys covering domains such as demographics and symptoms.  Of 7900+ survey responders, almost 6500  met the survey screening criteria and completed the survey.  Of those, 82.5% had been prescribed hydrocodone for more than one year.  The majority experienced some barriers, and 30% reported no changes in access to hydrocodone.  Of those who could no longer get hydrocodone

18.1% borrowed pain medications,

17.1% turned to marijuana,

13.1% used alcohol, and

2.3% used illicit drugs.

Most respondents had to visit their HCP more often (65.2%) and 30.3% reported some type of issue interacting with the pharmacy.  Most felt that the rescheduling was neither a fair, nor appropriate, solution to the abuse of hydrocodone (88.3%). For those still working, 46.2% reported that they had missed work because of the stricter regulations, and 27.7% reported having thoughts of suicide since the rescheduling. 

The significance of this survey highlights the unintended consequences on people with chronic pain caused by the rescheduling effort to impede hydrocodone abuse; the policy is negatively impacting untold numbers of people with chronic pain.  These consequences include suffering from being placed on less effective drugs, increased cost, inconvenience and negative influence on physician-patient and pharmacist-patient relationships.

NOTE:  The NFMCPA launched the follow-up hydrocodone survey,  Hydrocodone Rescheduling: The First Year.  Please consider taking part in this follow-up survey to help broaden the knowledge gap caused by this regulation and how it may be affecting people suffering with chronic pain. https://www.surveymonkey.com/r/Hydrocodone1Yr

Foundation for Chiropractic Progress Teams up with NFMCPA

IHCWest Forum 500x380FOR IMMEDIATE RELEASE

Foundation for Chiropractic Progress Teams Up with National Fibromyalgia & Chronic Pain Association:  Employer Perspectives on Chronic Pain in the Workplace at 2015 IHC FORUM West

CARMICHAEL, Calif. – November 16, 2015 -- The Foundation for Chiropractic Progress (F4CP), a not-for-profit organization dedicated to raising awareness about the value of chiropractic care, will sponsor Jan Chambers, president of the National Fibromyalgia & Chronic Pain Association (NFMCPA), as a speaker at the 2015 Institute for HealthCare Consumerism Forum West (IHC FORUM West), November 16-18, 2015, in Las Vegas, Nevada. The F4CP will support the workshop, “Employers Pay the Price for Chronic Pain in the Workplace,  November 18, 2015, 11:00 a.m. - 12:00 p.m., and host a discussion about the impact of chronic pain in the workplace and the utilization of chiropractic care as a frontline treatment option for pain relief.

“Pain is a growing epidemic in the workplace and costs $294 billion annually in lost workdays, medical expenses, and other benefit costs,” states Chambers, whose organization includes over 200,000 constituents and connects with more than 135,000 Facebook fans.  “Chronic pain is a leading cause of adult disability in the U.S., with employers, employees and the general public seeking information regarding treatment options.  Chiropractic care is a non-drug, non-invasive pain relief option representing opportunities for clinical and financial improvement.”

According to research, thirteen percent of the total workforce experienced a loss in productive time during a two-week period due to a common pain condition, including headache, back pain, arthritis, and musculoskeletal pain. Evidence confirms that the care provided by a doctor of chiropractic (DC) is often linked with better clinical outcomes, greater patient satisfaction and noteworthy cost savings. DC’s receive seven years of higher education positioning them to manage chronic pain effectively, especially as it relates to the musculoskeletal system.

F4CP Executive Vice President, Sherry McAllister, DC, explains, “We are honored to have Jan present on our behalf since she is a long-term sufferer of chronic pain and credits chiropractic care with delivering meaningful relief.”

About The Foundation for Chiropractic Progress

A not-for-profit organization, the Foundation for Chiropractic Progress informs and educates the general public about the many benefits associated with chiropractic care.   To learn more about the Foundation, please visit us on the web at www.f4cp.com and www.yes2chiropractic.com or call 866-901-F4CP (3427).

News: 2015 Treating and Preventing Conference Report and Available Videos

TAPOctober 2015 Treating and Preventing Chronic Pain Conference Report

Didn’t get a chance to come to Arlington or watch the live stream of the TAP Conference?  Together health professionals and patients learned cutting edge science, novel treatments, and skills during the innovative 2015 TAP Conference.  On-demand streaming recordings for the 2015 TAP Conference are available for $15 and can be purchased at paintap.org

A successful merging of health professionals and patients to learn together!  The inaugural Treating & Preventing Chronic Pain Conference in Arlington, Virginia, on October 8-10, 2015, presented by the National Fibromyalgia & Chronic Pain Association in partnership with the International Myopain Society was an educational event and a respectful exchange of questions and answers between the two groups.  An outstanding array of speakers on fibromyalgia and chronic pain gave cutting-edge scientific updates along with helpful new resources and treatment modalities.  At the same time, this CME event educated clinicians and researchers about a variety of treatment options and approaches that will ultimately help them provide better service to patients with these conditions.

At the opening reception on Thursday evening (October 8), presenters and patients co-mingled with members of the Chronic Pain Round Table Forum held earlier that afternoon.  During the Round Table, 28 stakeholders from industry, government agencies (FDA, NIAMS, NCCIH and PCORI), researchers and clinicians along with patients shared information concerning research funding, new research possibilities, better access to care for patients and a variety of other issues that transcended each of the groups.  We hope this venue of stakeholders will meet on an annual basis to discuss updates and positive movements toward rectifying some of the issues discussed at the forum.

More than 300 people attended the TAP conference, including approximately 200 via live video streaming in 25 countries including the USA, Canada, UK, Israel, Denmark, Japan, Saudi, Ukraine, Mexico, Czech Republic, New Zealand, France, Spain, Belgium, Portugal, Finland, Thailand, Moldova, Slovakia, Iraq, Italy, Germany, Argentina and Qatar.  Speakers answered participants’ questions, as they exchanged chats and Tweets with friends and other online audience members.  The keynote address on Friday morning given by world renowned fibromyalgia and chronic pain expert and researcher, Dr. Daniel Clauw of the University of Michigan discussed centralized pain and its role in chronic pain conditions.  Well-known pain specialist Dr. Lynn Webster reported on the NFMCPA Hydrocodone Rescheduling: The First 100 Days survey and the benefits of marijuana in the treatment of pain.

woman at podium 380x300Presentations on fibromyalgia and chronic pain covered  sleep; cervical spine conditions; myofascial pain; exercise; integrative medicine techniques including mindfulness and CBT; self-management including yoga and mindful movement; occupational therapy techniques; and myofascial pain self-management.  A question-and-answer period followed each presentation segment.  Friday night guest speaker, Dr. Lynn Webster, gave a moving presentation about his new book The Painful Truth, followed by a viewing of his documentary movie trailer of the same name.  Dr. Webster initiated an international chronic pain campaign to educate the public, medical communities and others about the impact chronic pain has on the lives of people affected by its unrelenting assault.

Saturday speakers included scientific research by Dr. Frank Rice on small fiber neuropathy in fibromyalgia, and neurologist Dr. Mike Sorrell discussed Myofascial Medicine.  German doctor and researcher Dr. Wolfgang Bauermeister demonstrated novel imaging of trigger points, which he feels is the major cause of musculoskeletal pain.  Dr. James Fricton, president of the International Myopain Society, educated about preventing chronic pain in the future and in the present for people who are already affected.

Saturday workshops included Dr. Andrew Holman, a Seattle area rheumatologist, discussing his study looking at fibromyalgia and PC3 positional cervical cord compression diagnostic MRI information.  A physical therapy approach to PC3 treatment was taught by Sue Horton, PT.  Dr. Cory Kingston, a chiropractor, discussed a technique that helps strengthen the neck and works to correct lordosis, the curvature of the neck.  Dr. Bauermeister demonstrated how to identify trigger points with ultrasound elastography and the benefits of different approaches to treatment.  Additional workshops ran concurrently:  Dr. Kim Jones delved into exercise and Dr. Kathleen Holton discussed nutrition to reduce chronic pain.  Dr. William Collinge introduced his NIH-funded  AwareHealth System, and online Personal Health Informatics program to reduce FM and chronic pain symptoms.

Speaker Barbara Kornblau, JD, OT focused on Reasonable Accommodation – based on ADA Regulations. Mary Biancalana’s workshop covered myofascial pain self-management.  Rachel Perrin, a professional make-up artist, taught beauty care and “liking who you see in the mirror.”  Author Elizabeth Christy spoke about her book, Why Does Mommy Hurt? and the challenges faced by young parents with chronic pain. Dr. Jim Fricton ran a workshop on his on-line Preventing Chronic Pain Campaign and explained to audience members how to access and use this information.

Throughout the two days of presentations and workshops, resources and information were provided  that could be incorporated into each person’s symptom management program.  Watch the Advocate Voice Newsletter for information on future  TAP Chronic Pain Conferences.  On-demand streaming recordings for the 2015 TAP Conference are available for $15 and can be purchased at paintap.org

Click here to review the entire TAP Chronic Pain program schedule. 

Click here for the TAP Chronic Pain speaker bios.

NFMCPA Publishes Article in Pain Medicine

sam 13The NFMCPA continues to break ground on advocacy and research fronts!  The survey work of principal investigator Jan Chambers and investigator Rae Gleason, has been accepted for publication in an upcoming edition of Pain Medicine, the highly regarded scientific journal of the American Academy of Pain Medicine.   The article, Hydrocodone Rescheduling: The First 100 Days, reflects the responses provided by the many thousands of people who participated in the survey.  Thank you for your support!!  And we extend appreciation to the co-authors on the article.

And -- Rae Gleason was listed as an investigator on a paper entitled, Fibromyalgia syndrome in need of effective treatments that was recently published in the Journal of Pharmacology and Experimental Therapeutics.  

Newsletter

Join our newsletter to stay updated on breaking research, advocacy and relationship news in the FM Community!

Contact us

  • Phone: 801-200-3627

Connect With Us

We're on Social Networks. Follow us & get in touch.


    

EV SSL